Search company, investor...


Founded Year



Acquired | Acquired

About Provepep

Provepep, formerly Synprosis, is a contract Development and manufacturing organization (CDMO - CMO) specialized in long peptide and/or complex peptides and proteins by chemical synthesis. We have developed innovative technologies and know-how in synthesis area.

Headquarters Location

59, avenue sainte victoire Zac Saint Charles

Fuveau, 13710,


+33 (0)4 42 60 82 86

Missing: Provepep's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Provepep's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Provepep News

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Oct 7, 2015

Published on October 7, 2015 at 6:04 AM· No Comments Provepep’s unique native ligation SEA technology used in chemical synthesis of long peptides and proteins Provepep, the peptide business unit of Provence Technologies Group, a specialist fine chemistry research group, today announces that it has successfully synthesized tens of mg of bioactive homodimer form of IL-10. Provepep is one of the two laboratories worldwide able to chemically synthesize therapeutic proteins and the only one using the SEA Technology. Provepep performed a solid-phase peptide synthesis (SPPS) using its proprietary SEA peptide ligation technology. Building upon the synthesis of different parts, SEA allows easy ligation of the complete sequence. The resulting monomer of 160 mer contains two disulfide bridges. This chemical synthesis, which is performed under Good Manufacturing Practice conditions, offers high-yield and high purity products. The process is easily reproducible. Provepep holds an exclusive licence from CNRS for SEA, a new and patented technology that reduces production costs by up to 40%. The SEA peptide ligation technique is an alternative to recombinant technologies that usually come with viral safety and contamination problems. It is also able to create proteins bearing non-natural amino-acids, something living organisms cannot do. “We managed to overcome major technological issues to allow the chemical synthesis and to achieve high activity for this Interleukin,” said Jean-Pierre Salles, CSO of Provepep. “After successfully finding a new synthetic pathway to purify Methylene Blue, we have proven yet again our technological know-how in chemical synthesis for long peptides and proteins.” This achievement paves the way for new generations of more affordable biological therapies, such as modified proteins. With this technology, Provepep targets pharmaceutical companies working on therapeutic proteins, fusion proteins and polyepitope vaccine projects. “Once more, our technology allowed us to produce through chemical synthesis a protein that is cheaper and purer than products stemming from recombinants technologies,” said Michel Feraud, CEO of Provence Technologies Group. “This new chemical synthesis should offer as many uses as recombinant technologies and facilitate the use of new biological therapies in immuno-regulation and inflammation. It also proves that Provepep is a natural leader in the market for chemical production of long peptides and proteins.” Source:

Provepep Frequently Asked Questions (FAQ)

  • When was Provepep founded?

    Provepep was founded in 2003.

  • Where is Provepep's headquarters?

    Provepep's headquarters is located at 59, avenue sainte victoire, Fuveau.

  • What is Provepep's latest funding round?

    Provepep's latest funding round is Acquired.

  • Who are the investors of Provepep?

    Investors of Provepep include Provence Technologies Group.

  • Who are Provepep's competitors?

    Competitors of Provepep include United Biomedical, Banyan Biomarkers, Esperance Pharmaceuticals, Ikaria, Isogenica and 11 more.

Compare Provepep to Competitors


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.


PhenoTech, Inc. was founded in 2003 and funded by BioAdvance in March 2004. PhenoTech was created to develop University of Pennsylvania technology for the discovery, development and commercialization of monoclonal antibodies (mAbs) to be used in blood diagnostic and blood therapeutic applications. The company is in the process of winding down operations.


Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Delphic Diagnostics

Delphic aims to provide a full suite of HIV diagnostics, from simple viral load testing through to advanced genetic tests, to pharmaceutical organisations and clinicians. Some of Delphic's tests are and have been developed internally. As part of MMC's investment, the University of Liverpool's Therapeutic Drug Monitoring service, was "˜spun in' to the business.

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.